Annual EBITDA
-$290.64 M
+$9.46 M+3.15%
December 31, 2023
Summary
- As of February 7, 2025, RVNC annual EBITDA is -$290.64 million, with the most recent change of +$9.46 million (+3.15%) on December 31, 2023.
- During the last 3 years, RVNC annual EBITDA has fallen by -$31.33 million (-12.08%).
- RVNC annual EBITDA is now -1058.38% below its all-time high of -$25.09 million, reached on December 31, 2011.
Performance
RVNC EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$28.63 M
+$1.73 M+5.70%
September 30, 2024
Summary
- As of February 7, 2025, RVNC quarterly EBITDA is -$28.63 million, with the most recent change of +$1.73 million (+5.70%) on September 30, 2024.
- Over the past year, RVNC quarterly EBITDA has increased by +$3.30 million (+10.32%).
- RVNC quarterly EBITDA is now -3743.09% below its all-time high of -$745.00 thousand, reached on December 31, 2012.
Performance
RVNC Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$268.87 M
+$3.30 M+1.21%
September 30, 2024
Summary
- As of February 7, 2025, RVNC TTM EBITDA is -$268.87 million, with the most recent change of +$3.30 million (+1.21%) on September 30, 2024.
- Over the past year, RVNC TTM EBITDA has dropped by -$25.50 million (-10.48%).
- RVNC TTM EBITDA is now -35990.34% below its all-time high of -$745.00 thousand, reached on December 31, 2012.
Performance
RVNC TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RVNC EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +3.1% | +10.3% | -10.5% |
| 3 y3 years | -12.1% | +57.7% | +0.9% |
| 5 y5 years | -110.9% | +29.6% | -71.8% |
RVNC EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -13.9% | +3.1% | at high | +82.9% | -16.0% | +10.4% |
| 5 y | 5-year | -85.7% | +3.1% | at high | +82.9% | -71.8% | +10.4% |
| alltime | all time | -1058.4% | +3.1% | -3743.1% | +82.9% | <-9999.0% | +10.4% |
Revance Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$28.63 M(-5.7%) | -$268.87 M(-1.2%) |
| Jun 2024 | - | -$30.36 M(-28.2%) | -$272.17 M(-6.8%) |
| Mar 2024 | - | -$42.29 M(-74.8%) | -$292.07 M(+1.7%) |
| Dec 2023 | -$290.64 M(-3.2%) | -$167.59 M(+424.9%) | -$287.14 M(+18.0%) |
| Sep 2023 | - | -$31.93 M(-36.5%) | -$243.37 M(-13.0%) |
| Jun 2023 | - | -$50.27 M(+34.6%) | -$279.74 M(-0.2%) |
| Mar 2023 | - | -$37.36 M(-69.8%) | -$280.42 M(-6.6%) |
| Dec 2022 | -$300.10 M(+17.6%) | -$123.82 M(+81.3%) | -$300.10 M(+29.1%) |
| Sep 2022 | - | -$68.29 M(+34.0%) | -$232.39 M(+0.3%) |
| Jun 2022 | - | -$50.95 M(-10.7%) | -$231.75 M(-5.9%) |
| Mar 2022 | - | -$57.03 M(+1.7%) | -$246.38 M(-3.4%) |
| Dec 2021 | -$255.18 M(-1.6%) | -$56.11 M(-17.1%) | -$255.18 M(-6.0%) |
| Sep 2021 | - | -$67.66 M(+3.2%) | -$271.38 M(-2.0%) |
| Jun 2021 | - | -$65.58 M(-0.4%) | -$276.87 M(+4.0%) |
| Mar 2021 | - | -$65.84 M(-8.9%) | -$266.20 M(+2.7%) |
| Dec 2020 | -$259.31 M(+65.7%) | -$72.30 M(-1.2%) | -$259.31 M(+12.0%) |
| Sep 2020 | - | -$73.14 M(+33.2%) | -$231.58 M(+16.3%) |
| Jun 2020 | - | -$54.92 M(-6.8%) | -$199.11 M(+10.1%) |
| Mar 2020 | - | -$58.95 M(+32.3%) | -$180.79 M(+15.5%) |
| Dec 2019 | -$156.52 M(+13.6%) | -$44.57 M(+9.6%) | -$156.52 M(+5.0%) |
| Sep 2019 | - | -$40.67 M(+11.1%) | -$149.09 M(+5.9%) |
| Jun 2019 | - | -$36.60 M(+5.5%) | -$140.81 M(+2.1%) |
| Mar 2019 | - | -$34.68 M(-6.6%) | -$137.87 M(+0.1%) |
| Dec 2018 | -$137.80 M | -$37.14 M(+14.7%) | -$137.80 M(+1.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$32.39 M(-3.8%) | -$136.17 M(+1.7%) |
| Jun 2018 | - | -$33.66 M(-2.7%) | -$133.96 M(+5.8%) |
| Mar 2018 | - | -$34.60 M(-2.6%) | -$126.66 M(+6.7%) |
| Dec 2017 | -$118.66 M(+36.8%) | -$35.52 M(+17.7%) | -$118.66 M(+8.5%) |
| Sep 2017 | - | -$30.17 M(+14.4%) | -$109.35 M(+13.3%) |
| Jun 2017 | - | -$26.37 M(-0.9%) | -$96.53 M(+2.6%) |
| Mar 2017 | - | -$26.61 M(+1.5%) | -$94.12 M(+8.5%) |
| Dec 2016 | -$86.74 M(+23.4%) | -$26.20 M(+51.0%) | -$86.74 M(+5.9%) |
| Sep 2016 | - | -$17.35 M(-27.6%) | -$81.87 M(-1.1%) |
| Jun 2016 | - | -$23.96 M(+24.6%) | -$82.79 M(+10.7%) |
| Mar 2016 | - | -$19.23 M(-9.8%) | -$74.81 M(+6.4%) |
| Dec 2015 | -$70.29 M(+40.0%) | -$21.33 M(+16.7%) | -$70.29 M(+12.7%) |
| Sep 2015 | - | -$18.27 M(+14.3%) | -$62.35 M(+8.8%) |
| Jun 2015 | - | -$15.98 M(+8.7%) | -$57.28 M(+6.5%) |
| Mar 2015 | - | -$14.71 M(+9.9%) | -$53.80 M(+7.2%) |
| Dec 2014 | -$50.19 M(+41.8%) | -$13.39 M(+1.4%) | -$50.19 M(+12.3%) |
| Sep 2014 | - | -$13.21 M(+5.6%) | -$44.69 M(+13.0%) |
| Jun 2014 | - | -$12.50 M(+12.7%) | -$39.54 M(+4.3%) |
| Mar 2014 | - | -$11.10 M(+40.7%) | -$37.92 M(+7.1%) |
| Dec 2013 | -$35.40 M(+28.6%) | -$7.88 M(-2.1%) | -$35.40 M(+25.3%) |
| Sep 2013 | - | -$8.06 M(-26.0%) | -$28.26 M(+39.9%) |
| Jun 2013 | - | -$10.88 M(+26.8%) | -$20.21 M(+116.7%) |
| Mar 2013 | - | -$8.58 M(+1051.7%) | -$9.32 M(+1151.7%) |
| Dec 2012 | -$27.52 M(+9.7%) | -$745.00 K | -$745.00 K |
| Dec 2011 | -$25.09 M | - | - |
FAQ
- What is Revance Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Revance Therapeutics?
- What is Revance Therapeutics annual EBITDA year-on-year change?
- What is Revance Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Revance Therapeutics?
- What is Revance Therapeutics quarterly EBITDA year-on-year change?
- What is Revance Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Revance Therapeutics?
- What is Revance Therapeutics TTM EBITDA year-on-year change?
What is Revance Therapeutics annual EBITDA?
The current annual EBITDA of RVNC is -$290.64 M
What is the all time high annual EBITDA for Revance Therapeutics?
Revance Therapeutics all-time high annual EBITDA is -$25.09 M
What is Revance Therapeutics annual EBITDA year-on-year change?
Over the past year, RVNC annual EBITDA has changed by +$9.46 M (+3.15%)
What is Revance Therapeutics quarterly EBITDA?
The current quarterly EBITDA of RVNC is -$28.63 M
What is the all time high quarterly EBITDA for Revance Therapeutics?
Revance Therapeutics all-time high quarterly EBITDA is -$745.00 K
What is Revance Therapeutics quarterly EBITDA year-on-year change?
Over the past year, RVNC quarterly EBITDA has changed by +$3.30 M (+10.32%)
What is Revance Therapeutics TTM EBITDA?
The current TTM EBITDA of RVNC is -$268.87 M
What is the all time high TTM EBITDA for Revance Therapeutics?
Revance Therapeutics all-time high TTM EBITDA is -$745.00 K
What is Revance Therapeutics TTM EBITDA year-on-year change?
Over the past year, RVNC TTM EBITDA has changed by -$25.50 M (-10.48%)